In sum, both ARBs and ACEIs effectively block RAS, whereas only ARBs appear to reinforce its counterregulatory system, via ACE2-angiotensin (1–7)-Mas1R axis and AT2R activation, a difference that could be critical in COVID-19 patients. The gene discussed is ACE2; the disease is COVID-19.